Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Trial of Retifanlimab and Difluoromethylornithine (DFMO) in Patients With Progressive High-Grade Glioma

NCT07468136 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07468136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07468136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Trial of Retifanlimab and Difluoromethylornithine (DFMO) in Patients With Progressive High-Grade Glioma
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 23, 2026
Completion date
October 25, 2030
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic oligodendroglioma, astrocytoma, idh-mutant, grade 3, astrocytoma, idh-mutant, grade 4, diffuse astrocytoma, glioblastoma, idh-wildtype, malignant glioma